H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2sup+/suppatients with diffuse midline glioma.

This is a publication. If there is no link to the publication on this page, you can try the pre-formated search via the search engines listed on this page.

Authors: Lena Immisch; George Papafotiou; Oliver Popp; Philipp Mertins; Thomas Blankenstein; Gerald Willimsky

Journal title: J Immunother Cancer

Journal publisher: BMJ

Published year: 2022

DOI identifier: 10.1136/jitc-2022-005535

ISSN: 2051-1426